1
|
Kim M, Noh K, Kim P, Kim JH, Choi BW, Singh R, Choi JH, Han SB, Kim SS, Lee EY, Bae MA, Shin D, Kim M, Ahn JH. Design, Synthesis, and Biological Evaluation of New 2,6,7-Substituted Purine Derivatives as Toll-like Receptor 7 Agonists for Intranasal Vaccine Adjuvants. J Med Chem 2024; 67:9389-9405. [PMID: 38787938 DOI: 10.1021/acs.jmedchem.4c00489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2024]
Abstract
TLR7/8 agonists are versatile immune stimulators capable of treating various diseases such as viral infections, autoimmune, and cancer. Despite the structural similarity of TLR7/8, their immune stimulation mechanisms and time-course responses significantly differ. In this study, a new series of TLR7-selective agonists was synthesized utilizing the economical building block 2,6-dichloropurine. Compound 27b showed the most potent activity on hTLR7 with an EC50 of 17.53 nM and demonstrated high hTLR7 selectivity (224 folds against TLR8). 27b effectively stimulated the secretion of proinflammatory cytokines in mouse macrophages and enhanced intranasal vaccine efficacy against influenza A virus in vivo. Assessment of humoral and mucosal antibody titers confirmed that 27b elevates IgG and IgA levels, protecting against both homologous and heterologous influenza viral infections. These findings suggest that 27b is a promising candidate as a vaccine adjuvant to prevent viral infections or as a robust immunomodulator with prolonged activity for treating immune-suppressed diseases.
Collapse
Affiliation(s)
- Morgan Kim
- Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea
| | - Kyungseob Noh
- Infectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, Republic of Korea
- Graduate School of New Drug Discovery and Development, Chungnam National University, Daejeon 34134, Republic of Korea
| | - Pyeongkeun Kim
- Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea
| | - Jae Ho Kim
- JD Bioscience, 208 Cheomdan-gwagiro, Buk-gu, Gwangju 61005, Republic of Korea
| | - Byeong Wook Choi
- Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea
| | - Ravi Singh
- Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea
| | - Jun-Ho Choi
- Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea
| | - Soo Bong Han
- Infectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, Republic of Korea
- Medicinal Chemistry and Pharmacology, University of Science and Technology, Daejeon 34113, Republic of Korea
| | - Seong Soon Kim
- Bio and Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea
| | - Eun-Young Lee
- JD Bioscience, 208 Cheomdan-gwagiro, Buk-gu, Gwangju 61005, Republic of Korea
| | - Myung Ae Bae
- Bio and Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea
| | - Daeho Shin
- Infectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, Republic of Korea
| | - Meehyein Kim
- Infectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, Republic of Korea
- Graduate School of New Drug Discovery and Development, Chungnam National University, Daejeon 34134, Republic of Korea
| | - Jin Hee Ahn
- Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea
- JD Bioscience, 208 Cheomdan-gwagiro, Buk-gu, Gwangju 61005, Republic of Korea
| |
Collapse
|
2
|
Ren SM, Chang JB, Liu RQ, Jin GY. The novel selective TLR7 agonist GY101 suppresses colon cancer growth by stimulating immune cells. Eur J Pharmacol 2024; 967:176383. [PMID: 38311281 DOI: 10.1016/j.ejphar.2024.176383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Revised: 01/24/2024] [Accepted: 02/01/2024] [Indexed: 02/10/2024]
Abstract
Toll-like receptor (TLR) 7, a transmembrane signal transduction receptor expressed on the surface of endosomes, has become an attractive target for antiviral and cancer immunotherapies. TLR7 can induce signal transduction by recognizing single-stranded RNA or its analogs, leading to the release of cytokines such as IL-6, IL-12, TNF-α and type-I IFN. Activation of TLR7 helps to enhance immunogenicity and immune memory by stimulating immune cells. Herein, we identified a novel selective TLR7 agonist, GY101, and determined its ability to activate TLR7. In summary, in vitro, compound GY101 significantly induced the secretion of IL-6, IL-12, TNF-α and IFN-γ in mouse splenic lymphocytes; in vivo, peritumoral injection of GY101 significantly suppressed colon cancer CT26, as well as poorly immunogenic B16-F10 and 4T1 cancer cell-derived tumor growth by activating the infiltration of lymphocytes and polarization of M2-like macrophages into M1-like macrophages. These results demonstrate that GY101, as a potent TLR7 agonist, holds great potential for cancer immunotherapy.
Collapse
Affiliation(s)
- Su-Mei Ren
- Research Center of Basic Medicine, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450001, Henan, China
| | - Jun-Biao Chang
- School of Pharmaceutical Science, Zhengzhou University, Zhengzhou, 450001, Henan, China
| | - Rui-Qi Liu
- School of Pharmaceutical Science, Zhengzhou University, Zhengzhou, 450001, Henan, China.
| | - Guang-Yi Jin
- School of Pharmaceutical Sciences, Nation-Regional Engineering Lab for Synthetic Biology of Medicine, International Cancer Center, Shenzhen University Health Science Center, Shenzhen University, Shenzhen, 518060, Guangdong, China; Shenzhen Conjugenix Pharmaceutical Technology Company, China.
| |
Collapse
|
3
|
He L, Zhang MY, Cox M, Zhang Q, Donnell AF, Zhang Y, Tarby C, Gill P, Subbaiah MAM, Ramar T, Reddy M, Puttapaka V, Li YX, Sivaprakasam P, Critton D, Mulligan D, Xie C, Ramakrishnan R, Nagar J, Dudhgaonkar S, Murtaza A, Oderinde MS, Schieven GL, Mathur A, Gavai AV, Vite G, Gangwar S, Poudel YB. Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncology. ACS Med Chem Lett 2024; 15:189-196. [PMID: 38352849 PMCID: PMC10860188 DOI: 10.1021/acsmedchemlett.3c00456] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2023] [Revised: 12/08/2023] [Accepted: 01/03/2024] [Indexed: 02/16/2024] Open
Abstract
Small molecule toll-like receptor (TLR) 7 agonists have gathered considerable interest as promising therapeutic agents for applications in cancer immunotherapy. Herein, we describe the development and optimization of a series of novel TLR7 agonists through systematic structure-activity relationship studies focusing on modification of the phenylpiperidine side chain. Additional refinement of ADME properties culminated in the discovery of compound 14, which displayed nanomolar reporter assay activity and favorable drug-like properties. Compound 14 demonstrated excellent in vivo pharmacokinetic/pharmacodynamic profiles and synergistic antitumor activity when administered in combination with aPD1 antibody, suggesting opportunities of employing 14 in immuno-oncology therapies with immune checkpoint blockade agents.
Collapse
Affiliation(s)
- Liqi He
- Research
and Development, Bristol Myers Squibb, 700 Bay Road, Redwood City, California 94063, United States
| | - Meng Yao Zhang
- Research
and Development, Bristol Myers Squibb, 700 Bay Road, Redwood City, California 94063, United States
| | - Matthew Cox
- Research
and Development, Bristol Myers Squibb, 700 Bay Road, Redwood City, California 94063, United States
| | - Qian Zhang
- Research
and Development, Bristol Myers Squibb, 700 Bay Road, Redwood City, California 94063, United States
| | - Andrew F. Donnell
- Research
and Development, Bristol Myers Squibb, Princeton, New Jersey 08543, United States
| | - Yong Zhang
- Research
and Development, Bristol Myers Squibb, Princeton, New Jersey 08543, United States
| | - Christine Tarby
- Research
and Development, Bristol Myers Squibb, Princeton, New Jersey 08543, United States
| | - Patrice Gill
- Research
and Development, Bristol Myers Squibb, Princeton, New Jersey 08543, United States
| | | | | | - Maheswara Reddy
- Biocon
Bristol Myers Squibb R&D Centre, Bangalore 560099, India
| | | | - Yi-Xin Li
- Research
and Development, Bristol Myers Squibb, 700 Bay Road, Redwood City, California 94063, United States
| | - Prasanna Sivaprakasam
- Research
and Development, Bristol Myers Squibb, Princeton, New Jersey 08543, United States
| | - David Critton
- Research
and Development, Bristol Myers Squibb, Princeton, New Jersey 08543, United States
| | - Dawn Mulligan
- Research
and Development, Bristol Myers Squibb, Princeton, New Jersey 08543, United States
| | - Chunshan Xie
- Research
and Development, Bristol Myers Squibb, Princeton, New Jersey 08543, United States
| | - Radha Ramakrishnan
- Research
and Development, Bristol Myers Squibb, Princeton, New Jersey 08543, United States
| | - Jignesh Nagar
- Biocon
Bristol Myers Squibb R&D Centre, Bangalore 560099, India
| | | | - Anwar Murtaza
- Research
and Development, Bristol Myers Squibb, Princeton, New Jersey 08543, United States
| | - Martins S. Oderinde
- Research
and Development, Bristol Myers Squibb, Princeton, New Jersey 08543, United States
| | - Gary L. Schieven
- Research
and Development, Bristol Myers Squibb, Princeton, New Jersey 08543, United States
| | - Arvind Mathur
- Research
and Development, Bristol Myers Squibb, Princeton, New Jersey 08543, United States
| | - Ashvinikumar V. Gavai
- Research
and Development, Bristol Myers Squibb, Princeton, New Jersey 08543, United States
| | - Gregory Vite
- Research
and Development, Bristol Myers Squibb, Princeton, New Jersey 08543, United States
| | - Sanjeev Gangwar
- Research
and Development, Bristol Myers Squibb, 700 Bay Road, Redwood City, California 94063, United States
| | - Yam B. Poudel
- Research
and Development, Bristol Myers Squibb, 700 Bay Road, Redwood City, California 94063, United States
| |
Collapse
|
4
|
DeYoung EG, Howe JM, Fang S, Reddy MM, Handel JP, Gillen Miller JT, Wheeler DR, Tumey LN. Synthesis and Optimization of 1-Substituted Imidazo[4,5- c]quinoline TLR7 Agonists. ACS Med Chem Lett 2023; 14:1358-1368. [PMID: 37849530 PMCID: PMC10577892 DOI: 10.1021/acsmedchemlett.3c00260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2023] [Accepted: 09/06/2023] [Indexed: 10/19/2023] Open
Abstract
TLR7 agonists have significant therapeutic potential in a variety of oncology and autoimmune applications. We recently reported a potent TLR7 selective agonist 1 that could be delivered by antibody-drug conjugate (ADC) technology to elicit potent anticancer activity. Herein we report synthetic chemistry and structure-activity relationship studies to develop TLR7 agonists with improved potency for next-generation ADC efforts. We found that the addition of hydrophobic acyl tails to parent compound 1 generally resulted in retained or improved TLR7 agonist activity without sacrificing the permeability or the selectivity over TLR8. In contrast, the addition of a simple alkyl tail at the same position resulted in a dramatic loss in potency. Molecular modeling was performed to provide a rationale for this dramatic loss in potency. We ultimately identified compounds 17b, 16b, and 16d as highly potent TLR7 agonists that potently induced the activation of mouse macrophages and hPBMCs at low-nanomolar concentrations.
Collapse
Affiliation(s)
- Emma G. DeYoung
- Binghamton University School of Pharmacy
and Pharmaceutical Sciences, Johnson
City, New York 13790, United States
| | - Justin M. Howe
- Binghamton University School of Pharmacy
and Pharmaceutical Sciences, Johnson
City, New York 13790, United States
| | - Siteng Fang
- Binghamton University School of Pharmacy
and Pharmaceutical Sciences, Johnson
City, New York 13790, United States
| | - Mullapudi Mohan Reddy
- Binghamton University School of Pharmacy
and Pharmaceutical Sciences, Johnson
City, New York 13790, United States
| | - Jillian P. Handel
- Binghamton University School of Pharmacy
and Pharmaceutical Sciences, Johnson
City, New York 13790, United States
| | - Jared T. Gillen Miller
- Binghamton University School of Pharmacy
and Pharmaceutical Sciences, Johnson
City, New York 13790, United States
| | - Daniel R. Wheeler
- Binghamton University School of Pharmacy
and Pharmaceutical Sciences, Johnson
City, New York 13790, United States
| | - L. Nathan Tumey
- Binghamton University School of Pharmacy
and Pharmaceutical Sciences, Johnson
City, New York 13790, United States
| |
Collapse
|
5
|
Samanta S, Mondal S. An expedient approach for the regioselective synthesis of novel 1,5,6,7-tetrahydro-2H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione derivatives via Fe (III)-mediated iodocyclization. Tetrahedron Lett 2022. [DOI: 10.1016/j.tetlet.2022.154223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
6
|
Talukdar A, Ganguly D, Roy S, Das N, Sarkar D. Structural Evolution and Translational Potential for Agonists and Antagonists of Endosomal Toll-like Receptors. J Med Chem 2021; 64:8010-8041. [PMID: 34107682 DOI: 10.1021/acs.jmedchem.1c00300] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Toll-like receptors (TLRs) are members of a large family of evolutionarily conserved pattern recognition receptors (PRRs), which serve as key components of the innate immune system by playing a pivotal role in sensing "nonself" ligands. Endosomal TLRs (TLR3, TLR7, TLR8, and TLR9) can recognize pathogen-derived nucleic acid and initiate an innate immune response because they react against both self- and non-self-origin nucleic acid molecules. Accordingly, both receptor agonists and antagonists are potentially useful in disparate clinical contexts and thus are globally sought after. Recent research has revealed that agonists and antagonists share an overlapping binding region. This Perspective highlights rational medicinal chemistry approaches to elucidate the structural attributes of small molecules capable of agonism or antagonism or of elegantly switching between the two. The structural evolution of different chemotypes can provide the framework for the future development of endosomal TLR agonists and antagonists.
Collapse
Affiliation(s)
- Arindam Talukdar
- Department of Organic and Medicinal Chemistry, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Kolkata 700032, West Bengal, India.,Academy of Scientific and Innovative Research, Ghaziabad 201002, Uttar Pradesh, India
| | - Dipyaman Ganguly
- IICB-Translational Research Unit of Excellence, Department of Cancer Biology and Inflammatory Disorders, CSIR-Indian Institute of Chemical Biology, CN6, Sector V, Salt Lake, Kolkata 700091, West Bengal, India.,Academy of Scientific and Innovative Research, Ghaziabad 201002, Uttar Pradesh, India
| | - Swarnali Roy
- Department of Organic and Medicinal Chemistry, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Kolkata 700032, West Bengal, India
| | - Nirmal Das
- Department of Organic and Medicinal Chemistry, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Kolkata 700032, West Bengal, India.,Academy of Scientific and Innovative Research, Ghaziabad 201002, Uttar Pradesh, India
| | - Dipika Sarkar
- Department of Organic and Medicinal Chemistry, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Kolkata 700032, West Bengal, India
| |
Collapse
|
7
|
Kaushik D, Kaur A, Petrovsky N, Salunke DB. Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles. RSC Med Chem 2021; 12:1065-1120. [PMID: 34355178 DOI: 10.1039/d1md00031d] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2021] [Accepted: 04/27/2021] [Indexed: 12/11/2022] Open
Abstract
Several synthetic heterocyclic small molecules like imiquimod, resiquimod, CL097, CL075, bromopirone, tilorone, loxoribine and isatoribine demonstrated TLR7/8 agonistic activity and relatively modest structural changes in such molecules result in major variation in the TLR7 and/or TLR8 activity. A strict dependency of the electronic configuration of the heterocyclic system was also observed to influence the agonistic activity. In the present review, an evolution of imidazole based TLR7/8 agonist from imidazoquinoline based scaffold is delineated along with the elaboration of detailed structure activity relationship (SAR) in each chemotype. The structural and activity details of not only the active compounds but also the related inactive compounds are included to better understand the SAR. TLR7/8 agonists are emerging as promising vaccine adjuvant candidates and the present SAR and structural information will provide a road map towards the identification of more potent and appropriate candidates for further drug discovery.
Collapse
Affiliation(s)
- Deepender Kaushik
- Department of Chemistry and Centre of Advanced Studies in Chemistry, Panjab University Chandigarh 160014 India
| | - Arshpreet Kaur
- Department of Chemistry and Centre of Advanced Studies in Chemistry, Panjab University Chandigarh 160014 India
| | - Nikolai Petrovsky
- Vaxine Pty Ltd 11 Walkley Avenue Warradale 5046 Australia.,College of Medicine and Public Health, Flinders University Bedford Park 5042 Australia
| | - Deepak B Salunke
- Department of Chemistry and Centre of Advanced Studies in Chemistry, Panjab University Chandigarh 160014 India .,National Interdisciplinary Centre of Vaccine, Immunotherapeutics and Antimicrobials, Panjab University Chandigarh 160014 India
| |
Collapse
|
8
|
Federico S, Pozzetti L, Papa A, Carullo G, Gemma S, Butini S, Campiani G, Relitti N. Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists. J Med Chem 2020; 63:13466-13513. [PMID: 32845153 DOI: 10.1021/acs.jmedchem.0c01049] [Citation(s) in RCA: 67] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Toll-like receptors (TLRs) are a class of proteins that recognize pathogen-associated molecular patterns (PAMPs) and damaged-associated molecular patterns (DAMPs), and they are involved in the regulation of innate immune system. These transmembrane receptors, localized at the cellular or endosomal membrane, trigger inflammatory processes through either myeloid differentiation primary response 88 (MyD88) or TIR-domain-containing adapter-inducing interferon-β (TRIF) signaling pathways. In the last decades, extensive research has been performed on TLR modulators and their therapeutic implication under several pathological conditions, spanning from infections to cancer, from metabolic disorders to neurodegeneration and autoimmune diseases. This Perspective will highlight the recent discoveries in this field, emphasizing the role of TLRs in different diseases and the therapeutic effect of their natural and synthetic modulators, and it will discuss insights for the future exploitation of TLR modulators in human health.
Collapse
Affiliation(s)
- Stefano Federico
- Department of Biotechnology, Chemistry and Pharmacy, Department of Excellence 2018-2022, University of Siena, via Aldo Moro 2, 53100, Siena, Italy
| | - Luca Pozzetti
- Department of Biotechnology, Chemistry and Pharmacy, Department of Excellence 2018-2022, University of Siena, via Aldo Moro 2, 53100, Siena, Italy
| | - Alessandro Papa
- Department of Biotechnology, Chemistry and Pharmacy, Department of Excellence 2018-2022, University of Siena, via Aldo Moro 2, 53100, Siena, Italy
| | - Gabriele Carullo
- Department of Biotechnology, Chemistry and Pharmacy, Department of Excellence 2018-2022, University of Siena, via Aldo Moro 2, 53100, Siena, Italy
| | - Sandra Gemma
- Department of Biotechnology, Chemistry and Pharmacy, Department of Excellence 2018-2022, University of Siena, via Aldo Moro 2, 53100, Siena, Italy
| | - Stefania Butini
- Department of Biotechnology, Chemistry and Pharmacy, Department of Excellence 2018-2022, University of Siena, via Aldo Moro 2, 53100, Siena, Italy
| | - Giuseppe Campiani
- Department of Biotechnology, Chemistry and Pharmacy, Department of Excellence 2018-2022, University of Siena, via Aldo Moro 2, 53100, Siena, Italy
| | - Nicola Relitti
- Department of Biotechnology, Chemistry and Pharmacy, Department of Excellence 2018-2022, University of Siena, via Aldo Moro 2, 53100, Siena, Italy
| |
Collapse
|
9
|
Zhang Z, Ohto U, Shibata T, Taoka M, Yamauchi Y, Sato R, Shukla NM, David SA, Isobe T, Miyake K, Shimizu T. Structural Analyses of Toll-like Receptor 7 Reveal Detailed RNA Sequence Specificity and Recognition Mechanism of Agonistic Ligands. Cell Rep 2019; 25:3371-3381.e5. [PMID: 30566863 DOI: 10.1016/j.celrep.2018.11.081] [Citation(s) in RCA: 90] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2018] [Revised: 10/08/2018] [Accepted: 11/21/2018] [Indexed: 12/18/2022] Open
Abstract
Toll-like receptor 7 (TLR7) is an innate immune receptor for single-stranded RNA (ssRNA) and has important roles in infectious diseases. We previously reported that TLR7 shows synergistic activation in response to two ligands, guanosine and ssRNA. However, the specific ssRNA sequence preference, detailed recognition mode of TLR7 and its ligand, and molecular determinants of TLR7 and TLR8 selectivity remain unknown. Here, we report on TLR7 from a large-scale crystallographic study combined with a multifaceted approach. We reveal that successive uridine-containing ssRNAs fully or moderately bind TLR7, whereas single uridine-containing ssRNAs have reduced affinities. We also reveal the detailed relationships between the chemical structures of ligands and their binding to TLR7. We demonstrate that an engineered TLR8 mutant alters its responsiveness to TLR7-specific ligands. Finally, we identify guanosine 2',3'-cyclic phosphate (2',3'-cGMP) as a possible endogenous ligand for TLR7 with greater affinity than guanosine. The abundant structural information will facilitate future development of treatments targeting TLR7.
Collapse
Affiliation(s)
- Zhikuan Zhang
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Umeharu Ohto
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
| | - Takuma Shibata
- Division of Innate Immunity, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
| | - Masato Taoka
- Department of Chemistry, Graduate School of Science and Technology, Tokyo Metropolitan University, Minami-osawa 1-1, Hachioji, Tokyo 192-0397, Japan
| | - Yoshio Yamauchi
- Department of Chemistry, Graduate School of Science and Technology, Tokyo Metropolitan University, Minami-osawa 1-1, Hachioji, Tokyo 192-0397, Japan
| | - Ryota Sato
- Division of Innate Immunity, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
| | - Nikunj M Shukla
- Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, 2-132 CCRB, 2231 6th Street SE, Minneapolis, MN 55455, USA
| | - Sunil A David
- Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, 2-132 CCRB, 2231 6th Street SE, Minneapolis, MN 55455, USA
| | - Toshiaki Isobe
- Department of Chemistry, Graduate School of Science and Technology, Tokyo Metropolitan University, Minami-osawa 1-1, Hachioji, Tokyo 192-0397, Japan
| | - Kensuke Miyake
- Division of Innate Immunity, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
| | - Toshiyuki Shimizu
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
| |
Collapse
|
10
|
McGowan DC. Latest Advances in Small Molecule TLR 7/8 Agonist Drug Research. Curr Top Med Chem 2019; 19:2228-2238. [DOI: 10.2174/1568026619666191009165418] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2019] [Revised: 08/23/2019] [Accepted: 09/03/2019] [Indexed: 12/31/2022]
Abstract
Toll-like receptors (TLRs) 7 and 8 play an important role in the activation of innate immune
cells in mammals. These evolutionarily conserved receptors serve as important sentinels in response to
infection. Activation of TLRs 7 and 8 triggers induction of a Th1 type innate immune response. The
emergence of new structural and small molecule information generated in the last decade has contributed
enormously to our understanding of this highly sophisticated process of innate immunity signaling.
This review will focus on recent developments in the small molecule activation of TLR 7 and 8.
Collapse
Affiliation(s)
- David C. McGowan
- Janssen Pharmaceutica, N.V., Turnhoutseweg 30, 2340 Beerse, Belgium
| |
Collapse
|
11
|
Bou Karroum N, Moarbess G, Guichou JF, Bonnet PA, Patinote C, Bouharoun-Tayoun H, Chamat S, Cuq P, Diab-Assaf M, Kassab I, Deleuze-Masquefa C. Novel and Selective TLR7 Antagonists among the Imidazo[1,2- a]pyrazines, Imidazo[1,5- a]quinoxalines, and Pyrazolo[1,5- a]quinoxalines Series. J Med Chem 2019; 62:7015-7031. [PMID: 31283223 DOI: 10.1021/acs.jmedchem.9b00411] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
The Toll-like receptors (TLRs) 7 and 8 play an important role in the immune system activation, and their agonists may therefore serve as promising candidate vaccine adjuvants. However, the chronic immune activation by excessive TLR stimulation is a hallmark of several clinically important infectious and autoimmune diseases, which warrants the search for TLR antagonists. In this study, we have synthesized and characterized a variety of compounds belonging to three heterocyclic chemical series: imidazo[1,2-a]pyrazine, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline. These compounds have been tested for their TLR7 or TLR8 agonistic and antagonistic activities. Several of them are shown to be selective TLR7 antagonists without any TLR7 or TLR8 agonistic activity. The selectivity was confirmed by a comparative ligand-docking study in TLR7 antagonist pocket. Two compounds of the pyrazolo[1,5-a]quinoxaline series (10a and 10b) are potent selective TLR7 antagonists and may be considered as promising starting points for the development of new therapeutic agents.
Collapse
Affiliation(s)
- Nour Bou Karroum
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247 F16, CNRS, Université de Montpellier , Faculté de Pharmacie , 15 avenue Charles Flahault , BP 14491, Montpellier 34093 Cedex 5 , France.,Tumorigenèse et Pharmacologie Antitumorale , Lebanese University, EDST , BP 90656, Fanar Jdeideh 1202 , Lebanon
| | - Georges Moarbess
- Tumorigenèse et Pharmacologie Antitumorale , Lebanese University, EDST , BP 90656, Fanar Jdeideh 1202 , Lebanon
| | - Jean-François Guichou
- CNRS, UMR 5048, INSERM, U105, Université de Montpellier, Centre de Biochimie Structurale , Montpellier F-34090 , France
| | - Pierre-Antoine Bonnet
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247 F16, CNRS, Université de Montpellier , Faculté de Pharmacie , 15 avenue Charles Flahault , BP 14491, Montpellier 34093 Cedex 5 , France
| | - Cindy Patinote
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247 F16, CNRS, Université de Montpellier , Faculté de Pharmacie , 15 avenue Charles Flahault , BP 14491, Montpellier 34093 Cedex 5 , France
| | - Hasnaa Bouharoun-Tayoun
- Laboratory of Immunology and Vector-Borne Diseases, Faculty of Public Health , Lebanese University , Fanar Jdeideh 1202 , Lebanon
| | - Soulaima Chamat
- Laboratory of Immunology and Vector-Borne Diseases, Faculty of Public Health , Lebanese University , Fanar Jdeideh 1202 , Lebanon.,Faculty of Medical Sciences , Lebanese University , Hadath 1500 , Lebanon
| | - Pierre Cuq
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247 F16, CNRS, Université de Montpellier , Faculté de Pharmacie , 15 avenue Charles Flahault , BP 14491, Montpellier 34093 Cedex 5 , France
| | - Mona Diab-Assaf
- Tumorigenèse et Pharmacologie Antitumorale , Lebanese University, EDST , BP 90656, Fanar Jdeideh 1202 , Lebanon
| | - Issam Kassab
- Tumorigenèse et Pharmacologie Antitumorale , Lebanese University, EDST , BP 90656, Fanar Jdeideh 1202 , Lebanon
| | - Carine Deleuze-Masquefa
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247 F16, CNRS, Université de Montpellier , Faculté de Pharmacie , 15 avenue Charles Flahault , BP 14491, Montpellier 34093 Cedex 5 , France
| |
Collapse
|
12
|
Pieters S, McGowan D, Herschke F, Pauwels F, Stoops B, Last S, Embrechts W, Scholliers A, Mostmans W, Van Dijck K, Van Schoubroeck B, Thoné T, De Pooter D, Fanning G, Rosauro ML, Khamlichi MD, Houpis I, Arnoult E, Jonckers THM, Raboisson P. Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonists. Bioorg Med Chem Lett 2018; 28:711-719. [PMID: 29366653 DOI: 10.1016/j.bmcl.2018.01.014] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2017] [Revised: 01/08/2018] [Accepted: 01/11/2018] [Indexed: 01/04/2023]
Abstract
The discovery of a novel series of highly potent quinazoline TLR 7/8 agonists is described. The synthesis and structure-activity relationship is presented. Structural requirements and optimization of this series toward TLR 7 selectivity afforded the potent agonist 48. Pharmacokinetic and pharmacodynamic studies highlighted 48 as an orally available endogenous interferon (IFN-α) inducer in mice.
Collapse
Affiliation(s)
- Serge Pieters
- Janssen Infectious Diseases Diagnostics BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium.
| | - David McGowan
- Janssen Infectious Diseases Diagnostics BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Florence Herschke
- Janssen Infectious Diseases Diagnostics BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Frederik Pauwels
- Janssen Infectious Diseases Diagnostics BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Bart Stoops
- Janssen Infectious Diseases Diagnostics BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Stefaan Last
- Janssen Infectious Diseases Diagnostics BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Werner Embrechts
- Janssen Infectious Diseases Diagnostics BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Annick Scholliers
- Janssen Infectious Diseases Diagnostics BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Wendy Mostmans
- Janssen Infectious Diseases Diagnostics BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Kris Van Dijck
- Janssen Infectious Diseases Diagnostics BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium
| | | | - Tine Thoné
- Janssen Infectious Diseases Diagnostics BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Dorien De Pooter
- Janssen Infectious Diseases Diagnostics BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Gregory Fanning
- Janssen Infectious Diseases Diagnostics BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Mari Luz Rosauro
- Villapharma Research S.L., Parque Tecnológico de Fuente Álamo, Ctra. El Estrecho-Lobosillo, km. 2.5-Av. Azul, 30320 Fuente Álamo de Murcia, Murcia, Spain
| | - Mourad Daoubi Khamlichi
- Villapharma Research S.L., Parque Tecnológico de Fuente Álamo, Ctra. El Estrecho-Lobosillo, km. 2.5-Av. Azul, 30320 Fuente Álamo de Murcia, Murcia, Spain
| | - Ioannis Houpis
- Janssen Infectious Diseases Diagnostics BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Eric Arnoult
- Janssen Research & Development L.L.C., 1400 McKean Rd, Spring House, PA 19454, United States
| | - Tim H M Jonckers
- Janssen Infectious Diseases Diagnostics BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Pierre Raboisson
- Janssen Infectious Diseases Diagnostics BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium
| |
Collapse
|